CR20220036A - Derivados de 2h-indazol y su uso en el tratamiento de enfermedades - Google Patents
Derivados de 2h-indazol y su uso en el tratamiento de enfermedadesInfo
- Publication number
- CR20220036A CR20220036A CR20220036A CR20220036A CR20220036A CR 20220036 A CR20220036 A CR 20220036A CR 20220036 A CR20220036 A CR 20220036A CR 20220036 A CR20220036 A CR 20220036A CR 20220036 A CR20220036 A CR 20220036A
- Authority
- CR
- Costa Rica
- Prior art keywords
- disease
- treatment
- indazole derivatives
- further provides
- invention further
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La presente invención hace referencia a derivados de 2H-indazol de fórmula (I’), o una sal farmacéuticamente aceptable de este, en los cuales todas las variables son tal como se definen en la memoria descriptiva, capaces de modular la actividad de IRAK4. Además, la invención proporciona un método para fabricar compuestos de la invención y métodos para su uso terapéutico. La invención también proporciona métodos para su preparación, para su uso médico, en particular, para su uso en el tratamiento y el control de enfermedades o trastornos que incluyen una enfermedad inflamatoria, una enfermedad autoinmunitaria, cáncer, una enfermedad cardiovascular, una enfermedad del sistema nervioso central, una enfermedad de la piel, una afección y enfermedad oftálmica, y una enfermedad ósea.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962867521P | 2019-06-27 | 2019-06-27 | |
PCT/US2020/039346 WO2020263967A1 (en) | 2019-06-27 | 2020-06-24 | 2h-indazole derivatives and their use in the treatment of disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20220036A true CR20220036A (es) | 2022-05-04 |
Family
ID=71608086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20220036A CR20220036A (es) | 2019-06-27 | 2020-06-24 | Derivados de 2h-indazol y su uso en el tratamiento de enfermedades |
Country Status (20)
Country | Link |
---|---|
US (1) | US20230002361A1 (es) |
EP (1) | EP3990432A1 (es) |
JP (1) | JP2022539374A (es) |
KR (1) | KR20220042132A (es) |
CN (1) | CN114585609A (es) |
AR (1) | AR119244A1 (es) |
AU (1) | AU2020304036A1 (es) |
BR (1) | BR112021026369A2 (es) |
CA (1) | CA3145043A1 (es) |
CL (1) | CL2021003458A1 (es) |
CO (1) | CO2022000657A2 (es) |
CR (1) | CR20220036A (es) |
IL (1) | IL289167A (es) |
JO (1) | JOP20210324A1 (es) |
MA (1) | MA56392A (es) |
MX (1) | MX2021015499A (es) |
PE (1) | PE20220517A1 (es) |
TW (1) | TW202116735A (es) |
UY (1) | UY38765A (es) |
WO (1) | WO2020263967A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11866405B2 (en) | 2020-12-10 | 2024-01-09 | Astrazeneca Ab | Substituted indazoles as IRAK4 inhibitors |
CN116940572A (zh) * | 2020-12-22 | 2023-10-24 | 渤健马萨诸塞州股份有限公司 | 作为irak4抑制剂的2h-吲唑衍生物及其在治疗疾病中的用途 |
IL303966A (en) * | 2020-12-22 | 2023-08-01 | Biogen Ma Inc | The history of imidazo[2,1-A]pyridine as IRAK4 inhibitors and their use in the treatment of diseases |
IL309941A (en) * | 2021-07-07 | 2024-03-01 | Biogen Ma Inc | Compounds to target degradation of IRAK4 proteins |
CN113651810B (zh) * | 2021-07-16 | 2023-10-13 | 上海毕得医药科技股份有限公司 | 一种3-甲酰基-1H-吡唑并[3,4-b]吡啶-5-羧酸甲酯的合成方法 |
WO2023152349A1 (en) | 2022-02-14 | 2023-08-17 | Astrazeneca Ab | Irak4 inhibitors |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
TW200616967A (en) * | 2004-06-24 | 2006-06-01 | Smithkline Beecham Corp | Novel indazole carboxamides and their use |
WO2007113596A1 (en) * | 2006-04-03 | 2007-10-11 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
CA2663100A1 (en) * | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase |
US7943617B2 (en) * | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
BG111378A (bg) * | 2013-01-14 | 2015-01-30 | Николай Цветков | Субституирани индазолови производни като in-vitro mao-b инхибитори |
JP6503338B2 (ja) * | 2013-03-15 | 2019-04-17 | バイオマリン ファーマシューティカル インコーポレイテッド | Hdac阻害剤 |
EP3183239B1 (en) * | 2014-08-22 | 2018-09-26 | Merck Patent GmbH | Indazoles |
JO3705B1 (ar) * | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
CN108026065A (zh) * | 2015-07-15 | 2018-05-11 | 奥列基因发现技术有限公司 | 作为irak-4抑制剂的吲唑及氮杂吲唑化合物 |
CN105503863A (zh) * | 2015-12-11 | 2016-04-20 | 南京华威医药科技开发有限公司 | 新型抗肿瘤化合物 |
CN105559944B (zh) * | 2015-12-14 | 2016-11-09 | 李雷 | 覆膜血管支架 |
EP3423446B1 (de) * | 2016-03-03 | 2020-09-16 | Bayer Pharma Aktiengesellschaft | Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
-
2020
- 2020-06-24 AU AU2020304036A patent/AU2020304036A1/en active Pending
- 2020-06-24 BR BR112021026369A patent/BR112021026369A2/pt not_active Application Discontinuation
- 2020-06-24 JO JOP/2021/0324A patent/JOP20210324A1/ar unknown
- 2020-06-24 WO PCT/US2020/039346 patent/WO2020263967A1/en active Application Filing
- 2020-06-24 TW TW109121728A patent/TW202116735A/zh unknown
- 2020-06-24 MX MX2021015499A patent/MX2021015499A/es unknown
- 2020-06-24 EP EP20740146.4A patent/EP3990432A1/en active Pending
- 2020-06-24 CN CN202080053737.3A patent/CN114585609A/zh active Pending
- 2020-06-24 UY UY0001038765A patent/UY38765A/es unknown
- 2020-06-24 JP JP2021577477A patent/JP2022539374A/ja active Pending
- 2020-06-24 KR KR1020227003147A patent/KR20220042132A/ko unknown
- 2020-06-24 MA MA056392A patent/MA56392A/fr unknown
- 2020-06-24 US US17/623,182 patent/US20230002361A1/en active Pending
- 2020-06-24 AR ARP200101792A patent/AR119244A1/es unknown
- 2020-06-24 CA CA3145043A patent/CA3145043A1/en active Pending
- 2020-06-24 CR CR20220036A patent/CR20220036A/es unknown
- 2020-06-24 PE PE2021002236A patent/PE20220517A1/es unknown
-
2021
- 2021-12-20 IL IL289167A patent/IL289167A/en unknown
- 2021-12-23 CL CL2021003458A patent/CL2021003458A1/es unknown
-
2022
- 2022-01-25 CO CONC2022/0000657A patent/CO2022000657A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2022000657A2 (es) | 2022-04-29 |
CA3145043A1 (en) | 2020-12-30 |
AU2020304036A1 (en) | 2022-01-06 |
EP3990432A1 (en) | 2022-05-04 |
KR20220042132A (ko) | 2022-04-04 |
PE20220517A1 (es) | 2022-04-07 |
TW202116735A (zh) | 2021-05-01 |
IL289167A (en) | 2022-02-01 |
CN114585609A (zh) | 2022-06-03 |
WO2020263967A1 (en) | 2020-12-30 |
US20230002361A1 (en) | 2023-01-05 |
UY38765A (es) | 2021-01-29 |
JP2022539374A (ja) | 2022-09-08 |
WO2020263967A8 (en) | 2021-01-28 |
MA56392A (fr) | 2022-05-04 |
BR112021026369A2 (pt) | 2022-05-17 |
MX2021015499A (es) | 2022-04-20 |
CL2021003458A1 (es) | 2022-08-19 |
JOP20210324A1 (ar) | 2023-01-30 |
AR119244A1 (es) | 2021-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20220036A (es) | Derivados de 2h-indazol y su uso en el tratamiento de enfermedades | |
JOP20210322A1 (ar) | مشتقات من إيميدازو[1 ،2-a] بيريدينيل واستخدامها في علاج مرض | |
Henry et al. | Underlying mechanisms of tinnitus: review and clinical implications | |
MX2021007592A (es) | Compuestos macrociclicos y su uso en el tratamiento de enfermedades. | |
NZ739211A (en) | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same | |
PH12018550049A1 (en) | Protein kinase inhibitor, preparation method and medical use thereof | |
PT1165085E (pt) | Derivados de ftalazina para tratar doencas inflamatorias | |
CY1110770T1 (el) | Χρηση των (r)-(αλογονοβενζυλοξυ) βενζυλαμινο-προπαναμιδιων ως επιλεκτικων διαμορφωτων διαυλου νατριου και/ή ασβεστιου | |
SG11201806438UA (en) | Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases | |
WO2021021979A3 (en) | Hdac6 inhibitors and uses thereof | |
CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
JOP20220102A1 (ar) | مثبطات المُسْتقبلة الأدرينِية adrac2 | |
UY39584A (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDINILO Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES | |
CR20230318A (es) | Derivados de 2h-indazol como inhibidores de irak4 y su uso en el tratamiento de enfermedades | |
CN111511373A (zh) | 神经***疾病治疗剂 | |
Jiang et al. | Lithium affects rat hippocampal electrophysiology and epileptic seizures in a dose dependent manner | |
WO2009003694A3 (en) | Method for treating diseases related to mitochondrial dysfunction | |
MX2021012579A (es) | Composiciones farmaceuticas a base de peptidos de colageno y dispositivos y metodos de produccion y uso de los mismos. | |
ATE437641T1 (de) | Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis | |
WO2019014322A8 (en) | KINASE INHIBITORS FOR THE TREATMENT OF DISEASES | |
US8182844B2 (en) | Use of Clerodendrum sp. for treating tic disorders or psychiatric disorders with sensorimotor gating deficits | |
Steinbach et al. | High-Frequency Spinal Cord Stimulation at 10 kHz for the Treatment of Chronic Neuropathic Pain After a II–III Degree Burn | |
Millichap et al. | Controlled evaluation of primidone and diphenylhydantoin sodium: comparative anticonvulsant efficacy and toxicity in children | |
WO2023055666A3 (en) | Implantable matrix for treating central nervous system disorders | |
MX2023000610A (es) | Inhibidor de trpv4 como agente terapeutico para enfermedades oculares. |